CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma
キーワード
概要
説明
RNA extraction from 150 patients archival tumor, fragments of 50 to 300 nucleotides size.
RNA preparation, hybridation, detection, scanning according to Nanostring manufacturer recommandations: obtention of CINSARC molecular signature Sensibility, specificity, prognostic value of the signature will be analyzed
日付
最終確認済み: | 12/31/2019 |
最初に提出された: | 01/26/2020 |
提出された推定登録数: | 01/28/2020 |
最初の投稿: | 01/29/2020 |
最終更新が送信されました: | 01/28/2020 |
最終更新日: | 01/29/2020 |
実際の研究開始日: | 09/14/2019 |
一次完了予定日: | 09/14/2020 |
研究完了予定日: | 05/14/2021 |
状態または病気
介入/治療
Other: CINSARC signature
段階
適格基準
研究の対象となる年齢 | 18 Years に 18 Years |
研究に適格な性別 | All |
サンプリング方法 | Probability Sample |
健康なボランティアを受け入れる | はい |
基準 | Inclusion Criteria: - Patients with ovarian adenocarcinoma treated in IUCTO Toulouse by primary chemotherapy and for whom diagnosis tumoral sample is available Exclusion Criteria: - None |
結果
主な結果の測定
1. The main endpoint is the sensitivity of the CINSARC signature to identify surgical resectability after neoadjuvant chemotherapy. [sept 2019-sept 2020]
二次的な結果の測定
1. Specificity of the CINSARC signature [sept 2019-sept 2020]
2. Positive predictive value of the signature [sept 2019-sept 2020]
3. Negative predictive value of the signature [sept 2019-sept 2020]
4. Global survival [sept 2019-sept 2020]
5. Progression Free survival [sept 2019-sept 2020]